Login / Signup

Retreatment with anti-PD-1 antibody in non-small cell lung cancer patients previously treated with anti-PD-L1 antibody.

Kohei FujitaYuki YamamotoOsamu KanaiMisato OkamuraMasayuki HashimotoKoichi NakataniSatoru SawaiTadashi Mio
Published in: Thoracic cancer (2019)
Patients treated with anti-PD-L1 antibodies for NSCLC received limited benefits from retreatment with anti-PD-1 antibodies.
Keyphrases
  • small cell lung cancer
  • single cell
  • cell therapy
  • advanced non small cell lung cancer
  • brain metastases